NASDAQ:BNR Burning Rock Biotech (BNR) Stock Price, News & Analysis $14.56 -1.76 (-10.75%) As of 02:59 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Burning Rock Biotech Stock (NASDAQ:BNR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Burning Rock Biotech alerts:Sign Up Key Stats Today's Range$14.51▼$16.1250-Day Range$15.85▼$23.4652-Week Range$2.80▼$41.72Volume22,716 shsAverage Volume26,223 shsMarket Capitalization$153.22 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Burning Rock Biotech (NASDAQ: BNR) is a precision oncology company specializing in the development and commercialization of next-generation sequencing (NGS)–based cancer diagnostics. The company’s core business revolves around liquid biopsy tests, which analyze circulating tumor DNA (ctDNA) from blood samples to detect genetic mutations associated with various solid tumors. By enabling noninvasive profiling of tumor genomics, Burning Rock Biotech aims to guide personalized therapy decisions and monitor treatment response in cancer patients. Founded in 2014 and headquartered in Guangzhou, China, Burning Rock Biotech launched its first clinical services in the mid-2010s and subsequently expanded its laboratory network across major Chinese cities. The company went public on the NASDAQ stock exchange in December 2015, opening access to international capital markets and enhancing its visibility in the global precision medicine arena. Over the years, Burning Rock Biotech has invested in upgrading its sequencing platforms and bioinformatics pipelines to broaden its test menu and improve turnaround times. Burning Rock Biotech offers an array of companion diagnostics and comprehensive genomic profiling assays that cover key oncogenes and tumor suppressor genes implicated in lung, colorectal, breast and other cancers. Its products include blood-based NGS panels for single-gene and multi-gene mutation detection, as well as tumor tissue assays for patients undergoing invasive biopsy procedures. The company also collaborates with pharmaceutical partners to develop targeted therapy trials, providing companion diagnostic support for drug development programs and regulatory submissions. The company is led by a management team composed of scientists and industry veterans with extensive experience in molecular diagnostics, oncology research and clinical laboratory operations. Under its leadership, Burning Rock Biotech continues to pursue strategic partnerships and technology enhancements, with the goal of extending its reach beyond China and into broader Asia-Pacific markets. As precision oncology evolves, the company remains focused on delivering high-quality, scalable testing solutions that support more informed treatment decisions for cancer patients worldwide.AI Generated. May Contain Errors. Read More Burning Rock Biotech Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks22nd Percentile Overall ScoreBNR MarketRank™: Burning Rock Biotech scored higher than 22% of companies evaluated by MarketBeat, and ranked 234th out of 299 stocks in the business services sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingBurning Rock Biotech has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageBurning Rock Biotech has only been the subject of 1 research reports in the past 90 days.Read more about Burning Rock Biotech's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Burning Rock Biotech is -18.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Burning Rock Biotech is -18.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBurning Rock Biotech has a P/B Ratio of 2.02. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Burning Rock Biotech's valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.65% of the float of Burning Rock Biotech has been sold short.Short Interest Ratio / Days to CoverBurning Rock Biotech has a short interest ratio ("days to cover") of 1.39, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Burning Rock Biotech has recently decreased by 1.12%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBurning Rock Biotech does not currently pay a dividend.Dividend GrowthBurning Rock Biotech does not have a long track record of dividend growth. News and Social MediaN/ANews SentimentN/A Company Ownership3.9 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $5,466,143.00 in company stock, which represents 3.5251% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Burning Rock Biotech insiders have bought more of their company's stock than they have sold. Specifically, they have bought $5,466,143.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders30.30% of the stock of Burning Rock Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions30.03% of the stock of Burning Rock Biotech is held by institutions.Read more about Burning Rock Biotech's insider trading history. Receive BNR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Burning Rock Biotech and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BNR Stock News HeadlinesBurning Rock Publishes 2025 Annual Report on Form 20-FApril 28, 2026 | globenewswire.comBurning Rock Announces Founder's Purchase of Its ADSsApril 2, 2026 | globenewswire.comDo NOT Buy SpaceX Before Seeing thisThe SpaceX IPO is scheduled for June 12, and CNBC is already calling it 'the big market event of 2026.' Former tech executive and angel investor Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before their major runs - says there's a way to claim a stake in SpaceX before it goes public. He's sharing the details now.May 22 at 1:00 AM | Brownstone Research (Ad)Burning Rock Announces Results of 2025 Annual General MeetingDecember 22, 2025 | globenewswire.comBurning Rock Announces 2025 Annual General Meeting to be Held on December 23, 2025December 1, 2025 | globenewswire.comBurning Rock Reports Third Quarter 2025 Financial ResultsNovember 20, 2025 | globenewswire.comBurning Rock's OncoGuide™ OncoScreen™ Plus CDx System Now Approved in Japan as a Companion Diagnostic for Capivasertib in Breast CancerSeptember 24, 2025 | globenewswire.comBurning Rock Biotech Reports Q2 2025 Financial ResultsSeptember 9, 2025 | msn.comSee More Headlines BNR Stock Analysis - Frequently Asked Questions How have BNR shares performed this year? Burning Rock Biotech's stock was trading at $20.15 on January 1st, 2026. Since then, BNR stock has decreased by 26.8% and is now trading at $14.74. How were Burning Rock Biotech's earnings last quarter? Burning Rock Biotech Limited Sponsored ADR (NASDAQ:BNR) posted its quarterly earnings data on Saturday, February, 14th. The company reported ($0.21) EPS for the quarter. The company earned $18.05 million during the quarter. Burning Rock Biotech had a negative trailing twelve-month return on equity of 9.98% and a negative net margin of 10.27%. When did Burning Rock Biotech's stock split? Shares of Burning Rock Biotech reverse split before market open on Wednesday, May 15th 2024.The 1-10 reverse split was announced on Wednesday, May 15th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, May 15th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Burning Rock Biotech IPO? Burning Rock Biotech (BNR) raised $196 million in an initial public offering on Friday, June 12th 2020. The company issued 13,500,000 shares at a price of $13.50-$15.50 per share. Morgan Stanley, BofA Securities and Cowen served as the underwriters for the IPO and CMBI and Tiger Brokers were co-managers. Who are Burning Rock Biotech's major shareholders? Top institutional investors of Burning Rock Biotech include Crcm LP (2.68%), Renaissance Technologies LLC (0.34%), Amova Asset Management Americas Inc. (0.28%) and Sumitomo Mitsui Trust Group Inc. (0.28%). View institutional ownership trends. How do I buy shares of Burning Rock Biotech? Shares of BNR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Burning Rock Biotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that Burning Rock Biotech investors own include Tesla (TSLA), NVIDIA (NVDA), Intel (INTC), Vertex Pharmaceuticals (VRTX), HubSpot (HUBS), NIO (NIO) and Alibaba Group (BABA). Company Calendar Last Earnings2/14/2026Today5/22/2026Next Earnings (Estimated)6/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 BNR's financial health is in the Yellow zone, according to TradeSmith. BNR has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorBusiness Services Industry Technology Services Sub-IndustryHealthcare Current SymbolNASDAQ:BNR CIK1792267 Webwww.brbiotech.com Phone86-185-0164-1666FaxN/AEmployees1,390Year Founded2014Profitability EPS (Trailing Twelve Months)($0.79) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$7.92 million Net Margins-10.27% Pretax Margin-9.97% Return on Equity-9.98% Return on Assets-6.69% Debt Debt-to-Equity RatioN/A Current Ratio2.99 Quick Ratio2.79 Sales & Book Value Annual Sales$77.16 million Price / Sales2.01 Cash FlowN/A Price / Cash FlowN/A Book Value$7.28 per share Price / Book2.02Miscellaneous Outstanding Shares10,520,000Free Float7,331,000Market Cap$155.06 million OptionableNot Optionable Beta1.49 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:BNR) was last updated on 5/22/2026 by MarketBeat.com Staff. From Our PartnersYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | SponsoredThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?On July 17th, the House passed the GENIUS Act - and at least one prominent Trump ally is raising alarms. Rep. ...Goldco Direct, LLC | SponsoredTo Avoid 67 Million Blackouts, Trump Signs Emergency Backing of New Energy TechPresident Trump has used emergency executive powers to back a new energy technology described as 326 times mor...Altimetry | SponsoredThis stock has 30 days of quiet leftA small power equipment company with $1.5 billion in orders is flying under the radar - but not for long. When...Behind the Markets | Sponsored"Computers are about to become obsolete" - George Gilder. Here’s why.George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and ...Eagle Publishing | SponsoredHidden on Tesla's filing: A $12 billion "super startup"Tesla's most recent SEC filing contains a single line showing $12 billion in revenue from a new venture Elon M...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Burning Rock Biotech Limited Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Burning Rock Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
